1-4 of 4
Jordan Chervin
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Clinical Factors but Not Somatic Mutations Predict for Survival in Patients with Myelofibrosis Undergoing Allogeneic Hematopoietic Cell Transplant: Analysis of the North American Myelofibrosis Transplant Outcome (NAMTO) Study

Helen Ajufo, Andriy Derkach, Raajit K. Rampal, Christopher Famulare, David Nemirovsky, Jordan Chervin, Vincent Ho, Vikas Gupta, Auro Viswabandya, H. Joachim Deeg, Tim Monahan, Tania Jain, Richard J. Jones, Jeanne Palmer, Aaron T. Gerds, Alla Keyzner, Jonathan Lagdameo, Alexandra Gomez-Arteaga, Koen Van Besien, Nikolai A. Podoltsev, Christian Puzo, Satyajit Kosuri, Idoroenyi Amanam, Roni Tamari
Journal: Blood
Blood (2023) 142 (Supplement 1): 3181.
https://doi.org/10.1182/blood-2023-173441
Published: 2023
Journal Articles

A Risk-Adapted Study to Assess the Efficacy of Enasidenib and Subsequent Response-Driven Addition of Azacitidine for Newly Diagnosed IDH2 -Mutant AML Patients: 3-Year Follow-up

Eytan Stein, Sheng F Cai, Ying Huang, Andrew Dunbar, Maria R. Baer, Wendy Stock, Tibor Kovacsovics, William G. Blum, Gary J. Schiller, Rebecca L. Olin, James M. Foran, Mark R. Litzow, Tara L. Lin, Prapti A. Patel, Matthew C. Foster, Michael M. Boyiadzis, Robert H. Collins, Jordan Chervin, Abigail B. Shoben, Jo-Anne Vergilio, Nyla A. Heerema, Leonard Rosenberg, Timothy Chen, Ashley O. Yocum, Franchesca Druggan, Sonja Marcus, Mona Stefanos, Molly Martycz, Brian J. Druker, Alice S. Mims, Uma Borate, Amy Burd, John C. Byrd, Ross L. Levine
Journal: Blood
Blood (2022) 140 (Supplement 1): 2016–2019.
https://doi.org/10.1182/blood-2022-166850
Published: 2022
Journal Articles

Enasidenib (ENA) Monotherapy with Addition of Azacitidine in Non-Responders Is Effective in Older Patients with Newly Diagnosed IDH2 Mutated Acute Myeloid Leukemia (AML): A Completed Phase 2/1b Sub-Study of the Beat AML Master Trial

Eytan M. Stein, MD, Ying Huang, MS, MA, Uma Borate, Maria R. Baer, MD, Wendy Stock, MD, Tibor Kovacsovics, MD, William Blum, MD, Gary J. Schiller, MD, Rebecca L. Olin, MD, James M. Foran, MD, Mark Litzow, MD, Tara Lin, MD, Prapti A. Patel, MD, Matthew C Foster, MD, Michael Boyiadzis, MD, Robert H. Collins, MD, Jo-Anne Vergilio, MD, Nyla A Heerema, PhD, Leonard Rosenberg, Ashley Owen Yocum, PhD, Timothy Chen, PhD, Franchesca Druggan, MSc, Sonja Marcus, MPH, Mona Stefanos, MBChB, Jordan Chervin, Abigail Shoben, Brian J. Druker, MD, Amy Burd, PhD, John C. Byrd, MD, Ross L. Levine, MD, Alice S. Mims, MD
Journal: Blood
Blood (2020) 136 (Supplement 1): 27–30.
https://doi.org/10.1182/blood-2020-143265
Published: 2020
Journal Articles

Enasidenib Is Highly Active in Previously Untreated IDH2 Mutant AML: Early Results from the Beat AML Master Trial

Eytan M. Stein, MD, Abigail Shoben, Uma Borate, MD, Maria R. Baer, MD, Wendy Stock, MD, Prapti A. Patel, MD, Tibor Kovacsovics, MD, William Blum, MD, Jo-Anne Vergilio, MD, Nyla A. Heerema, PhD, Leonard Rosenberg, Sonja Marcus, MPH, Mona Stefanos, MBChB, Jordan Chervin, Brian J. Druker, MD, Amy Burd, PhD, John C. Byrd, MD, Ross L. Levine, MD, Alice S. Mims, MD
Journal: Blood
Blood (2018) 132 (Supplement 1): 287.
https://doi.org/10.1182/blood-2018-99-118287
Published: 2018